Biomarin Pharmaceutical Inc (BMRN)

Days of sales outstanding (DSO)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Receivables turnover		3.83	3.74	3.95	3.58	3.55	4.46	4.76	4.08	4.35	4.89	4.88	4.46	4.58	4.07	4.43	4.76	4.47	4.49	3.96	4.03
DSO	days	95.20	97.47	92.40	101.95	102.79	81.76	76.60	89.45	83.89	74.58	74.80	81.89	79.64	89.78	82.46	76.73	81.61	81.30	92.07	90.63

March 31, 2024 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 3.83
= 95.20

Days Sales Outstanding (DSO) is a measure of how long it takes a company to collect its accounts receivable. A lower DSO indicates that the company is collecting payments faster, which is generally seen as a positive indicator of efficiency in managing its receivables.

Analyzing the DSO trend of Biomarin Pharmaceutical Inc over the past few quarters, we observe fluctuations in the DSO figures. In the latest quarter, March 31, 2024, the DSO stands at 95.20 days, a slight improvement from the previous quarter. This suggests that the company is managing its receivables slightly better.

Looking back over the previous quarters, we notice that Biomarin Pharmaceutical Inc experienced higher DSO numbers in some quarters, such as in Jun 30, 2019 and Mar 31, 2023, indicating delayed collections during those periods. Conversely, the company achieved lower DSO figures in other quarters, like in Dec 31, 2022 and Sep 30, 2022, demonstrating efficient management of accounts receivable during those periods.

Overall, Biomarin Pharmaceutical Inc's DSO trend appears to exhibit variability, indicating potential fluctuations in the company's collection efficiency. It would be advisable for the company to continue monitoring its DSO figures and implementing strategies to efficiently manage its accounts receivable to ensure consistent and timely collections.